These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 29018966)

  • 1. Safety and cost benefit of an ambulatory program for patients with low-risk neutropenic fever at an Australian centre.
    Teh BW; Brown C; Joyce T; Worth LJ; Slavin MA; Thursky KA
    Support Care Cancer; 2018 Mar; 26(3):997-1003. PubMed ID: 29018966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early hospital discharge followed by outpatient management versus continued hospitalization of children with cancer, fever, and neutropenia at low risk for invasive bacterial infection.
    Santolaya ME; Alvarez AM; Avilés CL; Becker A; Cofré J; Cumsille MA; O'Ryan ML; Payá E; Salgado C; Silva P; Tordecilla J; Varas M; Villarroel M; Viviani T; Zubieta M
    J Clin Oncol; 2004 Sep; 22(18):3784-9. PubMed ID: 15365075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early discharge and ambulatory care of low-risk patients with neutropenic fever in Australia.
    Hocking C; Taylor A; Hayward A
    Intern Med J; 2013 May; 43(5):591-5. PubMed ID: 23668271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outpatient therapy for febrile neutropenia: clinical and economic implications.
    de Lalla F
    Pharmacoeconomics; 2003; 21(6):397-413. PubMed ID: 12678567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cost analysis of febrile neutropenia management in Australia: ambulatory v. in-hospital treatment.
    Lingaratnam S; Worth LJ; Slavin MA; Bennett CA; Kirsa SW; Seymour JF; Dalton A; Koczwara B; Prince HM; O'Reilly M; Mileshkin L; Szer J; Thursky KA
    Aust Health Rev; 2011 Nov; 35(4):491-500. PubMed ID: 22126955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility of early discharge strategies for neutropenic fever: outcomes of a Victorian organisational readiness assessment and pilot.
    Lingaratnam S; Mellerick A; Worth LJ; Green M; Guy S; Kirsa S; Slavin M; Renwick W; Filshie R; Thursky KA
    Intern Med J; 2013 Sep; 43(9):979-86. PubMed ID: 23809725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and cost effectiveness of early hospital discharge of lower risk children with cancer admitted for fever and neutropenia.
    Bash RO; Katz JA; Cash JV; Buchanan GR
    Cancer; 1994 Jul; 74(1):189-96. PubMed ID: 8004575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of outpatient management for febrile neutropenia in children with cancer.
    Teuffel O; Amir E; Alibhai SM; Beyene J; Sung L
    Pediatrics; 2011 Feb; 127(2):e279-86. PubMed ID: 21220399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving the Management of Patients With Low-Risk Neutropenic Fever at the Cleveland Clinic Taussig Cancer Institute.
    Goodman LM; Estfan B; Montero A; Kunapareddy G; Lau J; Gallagher E; Best C; Tripp B; Moeller M; Bolwell B; Stevenson J
    J Oncol Pract; 2017 Mar; 13(3):e259-e265. PubMed ID: 28282274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential reduction of hospital stay length with outpatient management of low-risk febrile neutropenia in a regional cancer center.
    Nguyen M; Jacobson T; Torres J; Wann A
    Cancer Rep (Hoboken); 2021 Jun; 4(3):e1345. PubMed ID: 33635593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. National cost savings from an ambulatory program for low-risk febrile neutropenia patients in Australia.
    Tew M; Forster D; Teh BW; Dalziel K
    Aust Health Rev; 2019 Oct; 43(5):549-555. PubMed ID: 31526466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic comparison of home-care-based versus hospital-based treatment of chemotherapy-induced febrile neutropenia in children.
    Raisch DW; Holdsworth MT; Winter SS; Hutter JJ; Graham ML
    Value Health; 2003; 6(2):158-66. PubMed ID: 12641866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy.
    Cosler LE; Sivasubramaniam V; Agboola O; Crawford J; Dale D; Lyman GH
    Value Health; 2005; 8(1):47-52. PubMed ID: 15841893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness of outpatient treatment for febrile neutropaenia in adult cancer patients.
    Teuffel O; Amir E; Alibhai S; Beyene J; Sung L
    Br J Cancer; 2011 Apr; 104(9):1377-83. PubMed ID: 21468048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and costs of treating neutropenic fever in an outpatient setting.
    Del Prete SA; Ryan SP; Jacobson JS; Erichson RB; Weinstein PL; Grann VR
    Conn Med; 1999 Dec; 63(12):713-7. PubMed ID: 10659471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The economics of febrile neutropenia: implications for the use of colony-stimulating factors.
    Lyman GH; Kuderer N; Greene J; Balducci L
    Eur J Cancer; 1998 Nov; 34(12):1857-64. PubMed ID: 10023306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is parenteral chemotherapy safe in rural hospitals? A prospective audit of neutropenic fever in Albany Hospital, a regional West Australian cancer centre.
    Kennedy K; Auret K
    Intern Med J; 2017 Feb; 47(2):177-182. PubMed ID: 27753283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia.
    Elting LS; Lu C; Escalante CP; Giordano SH; Trent JC; Cooksley C; Avritscher EB; Shih YC; Ensor J; Bekele BN; Gralla RJ; Talcott JA; Rolston K
    J Clin Oncol; 2008 Feb; 26(4):606-11. PubMed ID: 18235119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Febrile neutropenia at the emergency department of a cancer hospital].
    Debey C; Meert AP; Berghmans T; Thomas JM; Sculier JP
    Rev Med Brux; 2011; 32(2):74-82. PubMed ID: 21688591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost of Cancer-Related Neutropenia or Fever Hospitalizations, United States, 2012.
    Tai E; Guy GP; Dunbar A; Richardson LC
    J Oncol Pract; 2017 Jun; 13(6):e552-e561. PubMed ID: 28437150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.